Search Results - "McLaughlin, Brigit"

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer by Scher, Howard I, Graf, Ryon P, Schreiber, Nicole A, Jayaram, Anuradha, Winquist, Eric, McLaughlin, Brigit, Lu, David, Fleisher, Martin, Orr, Sarah, Lowes, Lori, Anderson, Amanda, Wang, Yipeng, Dittamore, Ryan, Allan, Alison L, Attard, Gerhardt, Heller, Glenn

“…A blood test to determine whether to treat patients with metastatic castration-resistant prostate cancer (mCRPC) with an androgen receptor signaling (ARS)…”
Get more information

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer by Scher, Howard I, Graf, Ryon P, Schreiber, Nicole A, McLaughlin, Brigit, Lu, David, Louw, Jessica, Danila, Daniel C, Dugan, Lyndsey, Johnson, Ann, Heller, Glenn, Fleisher, Martin, Dittamore, Ryan

“…Abstract Background Circulating tumor cells (CTCs) expressing AR-V7 protein localized to the nucleus (nuclear-specific) identify metastatic…”
Get full text

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer by Scher, Howard I, Lu, David, Schreiber, Nicole A, Louw, Jessica, Graf, Ryon P, Vargas, Hebert A, Johnson, Ann, Jendrisak, Adam, Bambury, Richard, Danila, Daniel, McLaughlin, Brigit, Wahl, Justin, Greene, Stephanie B, Heller, Glenn, Marrinucci, Dena, Fleisher, Martin, Dittamore, Ryan

“…A critical decision in the management of metastatic castration-resistant prostate cancer (mCRPC) is when to administer an androgen receptor signaling (ARS)…”
Get more information

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer by Scher, Howard I, Graf, Ryon P, Schreiber, Nicole A, McLaughlin, Brigit, Jendrisak, Adam, Wang, Yipeng, Lee, Jerry, Greene, Stephanie, Krupa, Rachel, Lu, David, Bamford, Pascal, Louw, Jessica E, Dugan, Lyndsey, Vargas, Hebert A, Fleisher, Martin, Landers, Mark, Heller, Glenn, Dittamore, Ryan

“…The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate…”
Get full text

Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size by Pinzone, Marilia Rita, Graf, Erin, Lynch, Lindsay, McLaughlin, Brigit, Hecht, Frederick M, Connors, Mark, Migueles, Stephen A, Hwang, Wei-Ting, Nunnari, Giuseppe, O'Doherty, Una

“…The dynamics of HIV reservoir accumulation off antiretroviral therapy (ART) is underexplored. Levels of integrated HIV DNA in peripheral blood mononuclear…”
Get full text

Abstract 1740: Phenotypic, genomic, and clinical associations of Circulating Tumor Cells (CTCs) lacking epithelial biomarkers in metastatic Castration Resistant Prostate Cancer (mCRPC) by Graf, Ryon P., Wang, Yipeng, Schreiber, Nicole, McLaughlin, Brigit, Greene, Stephanie, Rodriguez, Angel, Jendrisak, Adam, Lee, Jerry, Landers, Mark, Dittamore, Ryan, Scher, Howard I.

“…Abstract Background: Epithelial Plasticity (EP) is a proposed mechanism of immune escape, resistance to programmed cell death, resistance to specific drugs,…”
Get full text

Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx) by Dittamore, Ryan Vance, Jendrisak, Adam, Schreiber, Nicole A., McLaughlin, Brigit, Graf, Ryon, Rodriguez, Angel, Fleisher, Martin, Lee, Jerry, Kelvin, James, Wang, Yipeng, Landers, Mark Andrew, Scher, Howard I.

“…Abstract only 5076 Background: Ra-223 prolongs life in mCRPC pts with symptomatic osseous metastasis with inconsistent effects on PSA. Survival times are…”
Get full text

Targeting reciprocal feedback inhibition: Apalutamide and everolimus in patients with metastatic castration-resistant prostate cancer (mCRPC) by Rathkopf, Dana E., Slovin, Susan F., Morris, Michael J., Danila, Daniel Costin, Delacruz, Anthony, Shelkey, Gregory, DeNunzio, Mia, McLaughlin, Brigit, Scher, Howard I.

“…Abstract only 204 Background: Studies in xenograft CRPC and PTEN-deficient prostate cancer models have shown synergistic anti-tumor activity of next-generation…”
Get full text

Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC) by Scher, Howard I., Graf, Ryon P, Schreiber, Nicole A., Winquist, Eric, McLaughlin, Brigit, Lu, David, Orr, Sarah, Fleisher, Martin, Lowes, Lori, Anderson, Amanda K. L., Wang, Yipeng, Dittamore, Ryan Vance, Allan, Alison L, Attard, Gerhardt, Heller, Glenn

“…Abstract only 273 Background: A previous analysis of 161 patients (pts) tested for nuclear-localized AR-V7(+) CTCs showed a therapy interaction between AR-V7…”
Get full text

Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A) by Scher, Howard I., Jendrisak, Adam, Schreiber, Nicole A., McLaughlin, Brigit, Graf, Ryon P, Rodriguez, Angel, Fleisher, Martin, Lee, Jerry, Kelvin, James, Wang, Yipeng, Landers, Mark Andrew, Dittamore, Ryan Vance

“…Abstract only 5070 Background: Prior response to A or E does not predict sensitivity to E following A or A following E. The detection of AR-V7 predicts…”
Get full text

Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) to prognosticate overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi) by Wise, David, Kelvin, James, Graf, Ryon, Schreiber, Nicole A., McLaughlin, Brigit, Fernandez, Luisa, Rivera, Normy, Petines, Bianca, Harvey, Melissa, Nguyen, Linda, Oh, Aaron, Horiuchi, Lee, Dittamore, Ryan Vance, Scher, Howard I.

“…Abstract only 194 Background: Upregulation of GR protein expression in metastatic biopsies from pts with CRPC has previously been shown to correlate with…”
Get full text

Single cell phenogenomic subtyping of circulating tumor cells (CTCs) identify intercellular tumor heterogeneity (het) and multiple resistance mechansisms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Scher, Howard I., Graf, Ryon, Jendrisak, Adam, Schreiber, Nicole A., McLaughlin, Brigit, Greene, Stephanie, Rodriguez, Angel, Fleisher, Martin, Lee, Jerry, Kelvin, James, Wang, Yipeng, Landers, Mark Andrew, Dittamore, Ryan Vance

“…Abstract only 139 Background: Genomic profiling of metastatic tumors can identify mCRPC pts w/ “actionable” targets. However, responses from this approach are…”
Get full text

Abstract 4954: Nuclear localized AR-V7 protein as a predictive biomarker for treatment selection in metastatic castration resistant prostate cancer (mCRPC) by Scher, Howard I., Lu, David, Schreiber, Nicole A., Louw, Jessica, Graf, Ryon P., Johnson, Ann, Jendrisak, Adam, Heller, Glenn, Bambury, Richard, Vargas Alverez, Herbert A., McLaughlin, Brigit, Wahl, Justin, Greene, Stephanie, Fleisher, Martin, Dittamore, Ryan

“…Abstract Background: A critical decision in the management of patients (pts) with mCRPC is when to administer an androgen receptor signaling (ARS) directed or…”
Get full text

CTC phenotype classifier to identify mCRPC patients (pts) with high genomic instability CTCs and to predict failure of androgen ecreptor signaling (AR Tx) and taxane (T) systemic therapies by Scher, Howard I., Jendrisak, Adam, Graf, Ryon, Schreiber, Nicole A., McLaughlin, Brigit, Greene, Stephanie, Rodriguez, Angel, Louw, Jessica, Dugan, Lyndsey, Leitz, Laura, Fleisher, Martin, Lee, Jerry, Wang, Yipeng, Landers, Mark Andrew, Dittamore, Ryan Vance

“…Abstract only…”
Get full text

AR-V7 and CTC heterogeneity biomarkers additively to predict patient (pt) outcomes with taxanes relative to approved AR targeted therapy by Scher, Howard I., Graf, Ryon, Schreiber, Nicole A., McLaughlin, Brigit, Lu, David, Louw, Jessica, Jendrisak, Adam, Greene, Stephanie, Rodriguez, Angel, Dugan, Lyndsey, Fleisher, Martin, Lee, Jerry, Wang, Yipeng, Landers, Mark Andrew, Dittamore, Ryan Vance

“…Abstract only…”
Get full text

Clinical validation of CTC subtype frequency to prognosis OS in mCRPC patients by Dittamore, Ryan Vance, Louw, Jessica, Schreiber, Nicole A., Graf, Ryon, Jendrisak, Adam, Johnson, Ann, Dugan, Lyndsey, McLaughlin, Brigit, Heller, Glenn, Fleisher, Martin, Wang, Yipeng, Marrinucci, Dena C., Scher, Howard I.

“…Abstract only 302 Background: CellSearch is an FDA cleared assay that enumerates intact CK+, DAPI+, CD45- cells via EpCAM capture. CTC number is prognostic for…”
Get full text

Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients by Scher, Howard I., Graf, Ryon, Louw, Jessica, Jendrisak, Adam, Johnson, Ann, Greene, Stephanie, Rodriguez, Angel, Schreiber, Nicole A., McLaughlin, Brigit, Dugan, Lyndsey, Fleisher, Martin, Lee, Jerry, Wang, Yipeng, Marrinucci, Dena C., Landers, Mark, Dittamore, Ryan Vance

“…Abstract only 163 Background: AR directed Tx, including Abiraterone (A) and Enzalutamide (E), prolong survival in patients with mCRPC and are FDA approved…”
Get full text